# Pixantrone (BBR 2778) in Patients With Refractory Acute Myelogenous Leukemia (AML)

> **NCT00106600** · PHASE1,PHASE2 · COMPLETED · sponsor: **CTI BioPharma** · enrollment: 12 (actual)

## Conditions studied

- Acute Myelogenous Leukemia

## Interventions

- **DRUG:** Pixantrone IV infusion

## Key facts

- **NCT ID:** NCT00106600
- **Lead sponsor:** CTI BioPharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-03
- **Primary completion:** —
- **Final completion:** 2007-03
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2023-09-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00106600

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00106600, "Pixantrone (BBR 2778) in Patients With Refractory Acute Myelogenous Leukemia (AML)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00106600. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*